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Eosinophilia is an easily recognized clinical entity ofdiverse etiologies including
allergic states such as atopy, asthma, and drug reactions, as well as helminth
infestations . One of the striking features in many of these conditions is the
selective nature of the eosinophilia, with other blood components found essen-
tially in normal numbers . An increase in the state of activation of eosinophils can
be observed concomitantly with an increase in eosinophil numbers in some of
these syndromes . For example, eosinophils from patients with the hypereosino-
philic syndrome show increased binding to antigen-antibody complexes (1), and
eosinophils from patients with helminth infections and allergic conditions have a
markedly increased capacity to adhere to and kill antibody-coated schistosomula
of Schistosoma mansoni (2, 3) when tested in vitro .
The observation of selective eosinophilia has led many investigators to postu-
late the existence of an "eosinophilopoietin" molecule . We have recently shown
that a murine cytokine, eosinophil differentiation factor (4), cross-reacted with
human cells selectively stimulating the proliferation, differentiation, and function
ofeosinophils (5), predicting the existence ofa human equivalent to this molecule .
Although no native human factor has been characterized, a recombinant human
(rh) molecule has now been identified and termed IL-5 (6, 7) which stimulates
the production of eosinophils in cultures of human bone marrow (7) . We show
here that rhIL-5 is also a powerful and selective stimulator of human eosinophil
function . IL-5 is thus the first hemopoietic factor whose elaboration in vivo can
explain the selective eosinophilia and eosinophil activation seen in disease .
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AIL-5andGranulocyte/Macrophage CSF(GM-CSF).
￿
Thehuman gene encodinghuman
I L-5 in the expression vector pcEXV-3 was transfected into COS cells by electroporation
as previously described (7) . The supernatant was collected after 4 d and concentrated by
ultrafiltration . Mock-transfected control supernatants were prepared in the same way .
rhGM-CSF, 99.4% pure, and with a specific activity of 10 6 U/ml, was a gift from Genetics
Institute (Cambridge, MA) .
Purification ofHuman Granulocytes .
￿
Peripheral blood was sedimented on dextran, and
the leukocyte-rich supernatant was centrifuged on a grandient of hypertonic Metrizamide
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FIGURE 1 . Titration of rhIL-5 (filled symbols)
and mock-transfected COS cell supernatant (open
symbols) on human eosinophil (circles) and neutro-
phil (squares) polarization . The percentage of po-
larized eosinophils (0) and neutrophils (*) in the
presence of 10 ng/ml rhGM-CSF is also shown .
(Nyegaard, Oslo, Norway) as previously described (8) . The eosinophil and neutrophil
preparations were always>90 and >95% pure, respectively .
Functional Assays.
￿
The antibody-dependent cell-mediated cytotoxicity, phagocytosis,
superoxide anion production, and polarization assays used have been described in detail
previously (9-11) .
Results
rhIL-5 was found to induce morphological changes on eosinophils . Cells thus
stimulated took on an irregular shape, the membrane ruffled, and the granules
concentrated on one end (polarization) ; these are changes typically induced by
other established activating agents (11, 12) . Eosinophils were polarized by rhIL-
5 in a dose-dependent manner and by rhGM-CSF but not by mock-transfected
COS cell supernatant (Fig . 1) . By contrast, neutrophils were polarized by rhGM-
CSF but not by rhIL-5 .
The morphological changes induced by rhIL-5 on eosinophils were accom-
panied by functional activation of these cells. rhIL-5 stimulated eosinophils but
not neutrophils to kill antibody-coated tumor cells while rhGM-CSF stimulated
both cell types (Fig . 2) . rhIL-5 stimulated eosinophils in a dose-dependent manner
and the levels of cytotoxicity were similar to those obtained with rhGM-CSF .
Similar results were obtained when rhIL-5 was examined for its ability to
stimulate phagocytosis of serum-opsonized baker's yeast . Eosinophils but not
neutrophils were stimulated by rhIL-5 at 2.5 and 1 .2% serum concentrations
(Table I) . Neutrophils, however, could be stimulated by rhGM-CSF .
The ability of rhIL-5 to stimulate the respiratory burst of eosinophils and
neutrophils was examined by measuring the levels of Oz- production . rhIL-5
stimulated directly the production ofOz- by eosinophils and to the same extent
as rhGM-CSF (Table II). In contrast, neither rhIL-5 nor rhGM-CSF directly
stimulated Ol - production by neutrophils . Because GM-CSF enhances the re-
sponse of neutrophils to a subsequent stimulus, neutrophils were preincubateda
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FIGURE 2 .
￿
Titration of rhIL-5 (O) mock-transfected COS cell supernatant (+) and rhGM-
CSF (") on human eosinophil- and neutrophil-mediated antibody-dependent cell-mediated
cytotoxicity of target cells .
TABLE I
rhIL-5 Stimulates Human Eosinophils but Not Neutrophils to Phagocytize Serum-
Opsonized Baker's Yeast
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i
0
rhlL-5 and mock-transfected COS cell supernatants were tested at 1 :10, and rhGM-CSF was tested at 10 ng/ml
final concentrations . Determinations were carried out in triplicate . In the case of eosinophils, values obtained
with rhIL-5 and rhGM-CSF were significantly different from those obtained with mock-transfected COS cell
supernatant (p < 0.01) . In the case ofneutrophils, rhGM-CSF, but not rhIL-5, values were significantly different
from those obtained with mock-transfected COS cell supernatant (p < 0.01) . Neither eosinophils nor neutrophils
showed significant phagocytosis in the absence of serum .
* Percentage of cells containing different numbers ofphagocytized yeast. A minimum of 200 cells were counted .
for 45 min at 37°C with rhIL-5, mock-transfected COS cell supernatant, or
rhGM-CSF, and then stimulated with 10-7 M f-Met-Leu-Phe. The 02- release
by neutrophils was enhanced by rhGM-CSF (15.7 nmol/106 cells) compared to
Stimuli
Serum
concen-
tration
0
Number of
Eosinophils
1,2
phagocytized
3,4
baker's
0
yeast per cell
Neutrophils
1,2 3,4
rhIL-5 2 .5 37* 52 .5 10 .5 58 21 21
Mock-transfected COS cell 2 .5 78 .5 18 .5 3 62 21 .5 16 .5
supernatant
rhGM-CSF 2 .5 55 32 13 13 .5 31 .5 55
rhIL-5 1 .2 79 .5 18 2 .5 81 .5 12 6 .5
Mock-transfected COS cell 1 .2 90 .5 9 0 .5 82 13 .5 4 .5
supernatant
rhGM-CSF 1 .2 80 .5 16 .5 3 48 27 2522 2
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TABLE II
Effect of rhIL-5 on the Direct Production of Superoxide Anion by Human
Eosinophils and Neutrophils
Eosinophils
￿
Neutrophils
Mock-trans-
rhlL-5
￿
fected COS
cell super_
￿
rhGM-(:SF
￿
PMA
￿
rhll:5
natant
Mock-trans-
fected COS
￿
rhGM
cell super-
￿
CSF
natant
PMA
1
￿
4.5* ± 0.5$
￿
1.0 ± 0.4
￿
4.2 ± 0.3:t
￿
41 .4 ± 0.9$
￿
0.8 ±0.1
￿
1 .4 ± 0.2
￿
1 .2 ± 0.3
￿
46.51 ± 1 .6
2
￿
7.6
￿
± 0.5:t
￿
2.7 ± 0.1
￿
6.3 ± 0.2$
￿
50.2 ± 1 .4$
￿
1 .9 t0.3
￿
2.0 ± 0.2
￿
2.2 ± 0.3
￿
60.0$ ± 0.9
rlil L-5 andmock-transfected COScell supernatant were tested at 1 :10 dilution. rhGM-CSF was used at 10 ng/ml.
PMA was used at 30 ng/ml.
* Values in nine] O4-/ 106 cells followed by SEM.
Values significantly different from mock-transfected COScells (p <0.05).
medium control (8 .5 nmol/106 cells), but not by rhIL-5 (8 .3 nmol/106 cells) or
mock-transfected COS cell supernatant (8.1 nmol/106 cells).
Discussion
We show here that rhIL-5, in addition to stimulating eosinophil proliferation,
is an activator of human eosinophil but not neutrophil function. Its selectivity
for human eosinophils makes IL-5 the molecule most likely to be responsible for
the increase in eosinophil numbers and for the state of activation of these cells
observed in allergy, parasitic infections, and hypereosinophilic syndromes.
In the present experiments, rhIL-5 altered the morphological appearance of
eosinophils to cells showing typical features of "polarization" including membrane
ruffling, an elongated shape, and the granules concentrated towards one end.
These morphological changes have been previously observed with chemotactic
factors and rhGM-CSF on neutrophils and eosinophils (11, 12) and probably
represent cytoskeletal changes occurring after cell activation (13). In addition,
rhIL-5 selectively stimulated several effector functions on human eosinophils but
not neutrophils.
Some of the functional effects of rhIL-5 reported in these experiments in vitro
appear similar to those taking place in vivo as seen in eosinophils from patients
with selective eosinophilia. For example, eosinophils from such patients have
been shown to have increased oxidative metabolism (14, 15) and an altered
morphology (1). Another feature of these eosinophils is their hypogranular
appearance suggestive of degranulation in vivo (1); however, in these studies we
have not examined whether IL-5 candirectly induce degranulation of eosinophils
in vitro.
The production of IL-5 in vivo may have important clinical implications.
Firstly, a selective increase in eosinophils, a cell type effective against several
parasites in vitro (8, 16), may facilitate the control of parasitic infestations.
Secondly, the continuous presence of large numbers of circulating eosinophils
may lead to tissue pathology as shown in cases of hypereosinophilic syndromes.
In some of these cases peripheral blood eosinophils were degranulated and
eosinophilic endomyocardial disease developed (17) . Thirdly, IL-5 may be pro-
duced by certain tumors. Some cases of carcinoma of the lung are associated
with eosinophilia (17, 18) and the extracted tumor can be shown to produce a
substance that preferentially stimulates eosinophils in vitro (18). In cases ofLOPEZ ET AL.
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lymphomas, eosinophilia has appeared before or at the time of diagnosis of the
tumor with peripheral eosinophil counts decreasing during remission but rising
again if a relapse occurs (19). Thus, IL-5 may be present in some paraneoplastic
syndromes and its detection may serve diagnostic purposes.
Finally, IL-5 becomes the third type of human CSF after GM-CSF (11, 20)
and IL-3 (21) capable of stimulating eosinophil proliferation and function in
man. The property of activating eosinophils, also shared with TNF-a (22), is not
obviously attributable to similarities in the primary structure of these molecules.
However, rhIL-5 and rhIL-3 do show a significant homology in their primary
sequence at the carboxy-terminal region-48% (including conservative substi-
tutions) over 19 amino acids in a significantly hydrophilic region of the mole-
cule-and it would be interesting to establish the relevance of this region for the
eosinophil-activating function of these two molecules.
Summary
Human rIL-5 was found to selectively stimulate morphological changes and
the function of human eosinophils. This molecule is thus a prime candidate for
the selective eosinophilia and eosinophil activation seen in disease.
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